Morgan Stanley’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-43
| Closed | -$272 | – | 7923 |
|
|
2022
Q4 | $272 | Sell |
43
-3,164
| -99% | -$17.5K | ﹤0.01% | 7617 |
|
|
2022
Q3 | $16K | Sell |
3,207
-7,027
| -69% | -$44.1K | ﹤0.01% | 6905 |
|
|
2022
Q2 | $64K | Sell |
10,234
-7,807
| -43% | -$26.3K | ﹤0.01% | 6503 |
|
|
2022
Q1 | $64K | Sell |
18,041
-808
| -4% | -$2.98K | ﹤0.01% | 6583 |
|
|
2021
Q4 | $95K | Buy |
18,849
+9,972
| +112% | +$60.1K | ﹤0.01% | 6480 |
|
|
2021
Q3 | $65K | Buy |
8,877
+1,009
| +13% | +$6.92K | ﹤0.01% | 6598 |
|
|
2021
Q2 | $68K | Buy |
7,868
+3,100
| +65% | +$26.4K | ﹤0.01% | 6531 |
|
|
2021
Q1 | $52K | Hold |
4,768
| – | – | ﹤0.01% | 6339 |
|
|
2020
Q4 | $47K | Sell |
4,768
-1
| -0% | -$7 | ﹤0.01% | 6181 |
|
|
2020
Q3 | $26K | Sell |
4,769
-350
| -7% | -$2.1K | ﹤0.01% | 5965 |
|
|
2020
Q2 | $30K | Sell |
5,119
-19
| -0.4% | -$110 | ﹤0.01% | 5879 |
|
|
2020
Q1 | $19K | Sell |
5,138
-700
| -12% | -$3.62K | ﹤0.01% | 5837 |
|
|
2019
Q4 | $36K | Buy |
5,838
+761
| +15% | +$9.67K | ﹤0.01% | 5944 |
|
|
2019
Q3 | $70K | Sell |
5,077
-6,164
| -55% | -$102K | ﹤0.01% | 5576 |
|
|
2019
Q2 | $166K | Buy |
11,241
+5,694
| +103% | +$153K | ﹤0.01% | 5103 |
|
|
2019
Q1 | $233K | Sell |
5,547
-4,878
| -47% | -$205K | ﹤0.01% | 4980 |
|
|
2018
Q4 | $434K | Sell |
10,425
-2,019
| -16% | -$90.8K | ﹤0.01% | 4872 |
|
|
2018
Q3 | $600K | Buy |
12,444
+1,494
| +14% | +$74.8K | ﹤0.01% | 4889 |
|
|
2018
Q2 | $519K | Buy |
10,950
+5,208
| +91% | +$289K | ﹤0.01% | 5073 |
|
|
2018
Q1 | $353K | Sell |
5,742
-377
| -6% | -$19.9K | ﹤0.01% | 5190 |
|
|
2017
Q4 | $328K | Buy |
6,119
+1,100
| +22% | +$65.4K | ﹤0.01% | 5204 |
|
|
2017
Q3 | $338K | Buy |
5,019
+3,206
| +177% | +$184K | ﹤0.01% | 5100 |
|
|
2017
Q2 | $98K | Buy |
1,813
+250
| +16% | +$11.6K | ﹤0.01% | 5644 |
|
|
2017
Q1 | $56K | Hold |
1,563
| – | – | ﹤0.01% | 5798 |
|
|
2016
Q4 | $50K | Buy |
+1,563
| New | +$57.3K | ﹤0.01% | 5752 |
|
Morgan Stanley's FSTX Position: Q1 2023 in Review
Morgan Stanley sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 43 shares — an estimated $272 sold.
Morgan Stanley first reported a position in FSTX in Q4 2016 and held it in 25 quarters. The position peaked at $600K in Q3 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Morgan Stanley reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 43 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $272.
- Morgan Stanley first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 25 quarters.
- Morgan Stanley's F-star Therapeutics, Inc. Common Stock position peaked at $600K in Q3 2018.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.